bullish
Eoflow: Ozempic and Wegovy Reducing Need for Disposable Insulin Injection Devices + Ongoing Lawsuit?
1.2k Views05 Oct 2023 20:25
Eoflow's share price has dropped 27% lower than the proposed tender offer price of 30,000 won. In this insight, we discuss two major factors have negatively impacted Eoflow's share price recently.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Eoflow: Outlook After Trading Resumes on 16 November16 Nov 2023
- Medtronic's M&A of Eoflow Timeline Postponed26 Oct 2023
- Eoflow: Temporary Trading Suspension11 Oct 2023
- Eoflow: Ozempic and Wegovy Reducing Need for Disposable Insulin Injection Devices + Ongoing Lawsuit?05 Oct 2023
- EOFLOW/Medtronic Tender: Proposed Preliminary Injunction Is a Problem05 Oct 2023
- Eoflow's US Subsidiary (Nephria Bio)'s Technology in MXene Advanced Material21 Aug 2023
- Insulet's Lawsuit Against Eoflow, Medtronic's Tender Offer, and Eoflow's "Special Sauce"09 Aug 2023
x